I'm a member

Factor VIII, (human), an antihemophilic factor (AHF), is a protein found in normal plasma that is necessary for clot formation. Factor VIII (human) is prepared from pooled human venous plasma obtained from suitable whole-blood donors. Administration of an AHF can temporarily correct the coagulation defect of patients with classical hemophilia (hemophilia A). It is needed for transformation of prothrombin (II) to thrombin by the intrinsic pathway.

Factor VIII (recombinant) is a biosynthetic blood coagulation preparation prepared using recombinant DNA technology. Factor VIII (recombinant) is structurally similar to endogenous human Factor VIII and produces the same biologic effects. The most important difference between Factor VIII (recombinant) and Factor VIII  (human) is that the biosynthetic preparation is associated with a substantially reduced risk of contamination with blood-borne human viruses.

Factor VIII (porcine) is a protein found in normal plasma that is necessary for clot formation. Factor VIII (porcine), which is prepared from porcine plasma (porcine Factor VIII:C), is structurally similar to endogenous human Factor VIII and produces the same biologic effects.

Factor IX (human) is a highly purified, sterile, lyophilized concentrate of blood coagulation Factor IX that is prepared from human plasma. It is obtained from a prothrombin complex concentrate derived by cryoprecipitation of pooled human venous plasma.

Factor IX (complex) also called prothrombin complex concentrate (PCC), is a sterile, lyophilized concentrate of blood coagulation factors II, VII, IX, and X. It is derived from fresh venous plasma obtained from healthy human donors.

Factor IX (recombinant) is a purified protein produced by recombinant DNA technology. A genetically engineered Chinese hamster ovary cell line secretes recombinant factor IX into a defined cell culture medium. This is then purified by a chromatography purification process.

FDA APPROVED INDICATIONS FOR FACTOR VIII

FDA APPROVED INDICATIONS FOR FACTOR IX

IDENTIFICATION

Generic Name: Factor VIII (human)
Brand Names: Alphanate®, Hemofil M®, Koate-DVI®, Monoclate-P®  

Generic Name: Factor VIII (recombinant)
Brand Names: Helixate®, Kogenate®, Recombinate®, ReFacto®, Xyntha®, Advate®

Generic Name: Factor VIII/VWF
Brand Names: Humate-P®, Wilate®

Generic Name: Factor IX (human)
Brand Names: AlphaNine SD®, Mononine®

Generic Name: Factor IX (complex)
Brand Names: Bebulin VH®, Profilnine SD®, Proplex T®

Generic Name: Factor IX (recombinant)
Brand Names: BeneFix®

Factor VIII is considered medically necessary for the following disease states:

• Classical hemophilia (hemophilia A)
• Patients with hemophilia A and HIV-infection
• Patients with hemophilia A and inhibitors to antihemophilic factor
• Patients with acquired hemophilia
• Von Willebrand disease

Factor VIII (recombinant) is considered medically necessary for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children (0-16) with hemophilia A with no pre-existing joint damage.

Factor IX is considered medically necessary for the following disease states:

1/30/2002: Factor VIII (Human), Factor VIII (Recombinant) and Factor VIII (Porcine) policies combined into one policy titled "Factor VIII"; Prior authorization deleted

4/24/2002: Type of Service and Place of Service deleted. Code Reference section completed

11/6/2002: Koate-DVI® added, Koate-P® and Koate-HP® deleted

8/17/2004: Code Reference section updated, ICD-9 diagnosis code 286.1, 286.4, 286.5 added, HCPCS S9345 added

9/24/2004: Code Reference section updated, CPT code 36440, 85244 deleted

10/29/2006: Factor VIII and Factor IX policies combined

9/12/2007: Added Mississippi Comprehensive Health Insurance Risk Pool Association will no longer provide benefits for antihemophilic factor, factor VIII, factor IX, factor concentrate or factorate products of any kind and services or related supplies received on an outpatient basis effective August 1, 2007, to Policy Exceptions

12/31/2008: Code Reference section updated per 2009 CPT/HCPCS revisions.

01/01/2009: Accredo preferred provider information removed. BCBSMS information added.

6/30/2009: New HCPC code Q2023 added to covered table.

8/26/2009: Policy statement updated to include medically necessary indications for VIII for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children (0-16) with hemophilia A with no pre-existing joint damage. 

12/15/2009: Coding Section revised for 2010 CPT4 and HCPCS revisions

03/08/2010:  Description section was updated with Humate-P®, Wilate®.  Also added brand names (ReFacto®, Xyntha® and Advate®) for Factor VIII (recombinant). Policy Section updated with coverage for Von Willebrand disease for Factor VIII.  Policy Exceptions Section updated to remove Risk Pool language. HCPCS code J7185 & J7187 were added to Covered Codes for Factor VIII.

02/28/2011:  Added new HCPCS code J7184 for Wilate® to the Code Reference section.

American Hospital Formulary Services 1998

Micromedex, 1998, 2006

BeneFix® Prescribing Information

Helixate® Prescribing Information

Kogenate® Prescribing Information

Wilate® Prescribing Information

The code(s) listed below are ONLY covered if the procedure is performed according to the "Policy" section of this document.

Covered Codes for Factor VIII

Covered Codes for Factor IX

Top